Advertisement

Supportive Care in Cancer

, Volume 12, Issue 3, pp 208–209 | Cite as

Pruritus in a patient with advanced cancer successfully treated with continuous infusion of granisetron

  • Giampiero PorzioEmail author
  • Federica Aielli
  • Filomena Narducci
  • Katia Cannita
  • Domenico Piccolo
  • Paolo Marchetti
Short Communication

Abstract

We present a case of a patient with advanced cancer affected by severe pruritus not related with cholestasis and/or opioid treatment successfully treated with subcutaneous continuous infusion of granisetron (3 mg/24 h diluted in normal saline via a disposable elastomeric infusion device). Confirmatory studies with a control group are warranted to confirm these preliminary results.

Keywords

Pruritus Granisetron 

References

  1. 1.
    Albares MP, Betlloch I, Guijarro J, Vergara G, Pascual JC, Botella R (2003) Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron. Br J Dermatol 148:376–377CrossRefPubMedGoogle Scholar
  2. 2.
    Chung KC, Chin A, Gill MA (1995) Stability of granisetron hydrochloride in a disposable elastomeric infusion device. Am J Health Syst Pharm 52:1541–1543PubMedGoogle Scholar
  3. 3.
    Dimitrou V, Voyagis GS (1999) Opioid-induced pruritus: repeat vs single dose ondansetron administration in preventing pruritus after intrathecal morphine. Br J Anaest 83:822–826Google Scholar
  4. 4.
    Krajnik M, Zylicz Z (2001) Understanding pruritus in systemic disease. J Pain Symptom Manage 21:151–168CrossRefPubMedGoogle Scholar
  5. 5.
    Lindstone V, Thorns A (2001) Pruritus in cancer patients. Cancer Treat Rev 27:305–312CrossRefPubMedGoogle Scholar
  6. 6.
    Murphy M, Reaich D, Pai P, Finn P, Carmichael AJ (2003) A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 148: 314–317CrossRefPubMedGoogle Scholar
  7. 7.
    Schworer H, Hartmann H, Ramadori G (1995) Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 61:33–37CrossRefPubMedGoogle Scholar
  8. 8.
    Trissel LA, Gilbert DL, Martinez JP (1997) Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health Syst Pharm 54:56–60PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Giampiero Porzio
    • 1
    • 4
    Email author
  • Federica Aielli
    • 1
  • Filomena Narducci
    • 1
  • Katia Cannita
    • 2
  • Domenico Piccolo
    • 3
  • Paolo Marchetti
    • 2
  1. 1.Supportive Care and Rehabilitation Unit, Medical Oncology DepartmentUniversity of L’AquilaL’AquilaItaly
  2. 2.Medical Oncology DepartmentUniversity of L’AquilaL’AquilaItaly
  3. 3.Dermatological Oncology UnitUniversity of L’AquilaL’AquilaItaly
  4. 4.Dipartimento di Medicina SperimentaleUniversità degli StudiL’AquilaItaly

Personalised recommendations